Showing 1501-1510 of 1732 results for "".
- Hemicraniectomy for Massive Stroke: Finally an Answer?https://practicalneurology.com/columns/practice-management/hemicraniectomy-for-massive-stroke-finally-an-answer/31210/Hemicraniectomy Presents a Viable Option for Massive Stroke ManagementIn the ongoing debate within vascular neurology regarding the efficacy of hemicraniectomy for malignant hemispheric strokes, recent findings offer significant insights. Malignant infarctions, characterized by extensive cerebral sw
- Vascular Clinichttps://practicalneurology.com/diseases-diagnoses/stroke/PN0505Vascular-pdf/31460/Intracranial stenosis, responsible for 10-15% of all strokes and more prevalent among non-Caucasian populations such as Asians and African Americans, remains a critical yet under-researched area in vascular neurology. Historically, the medical management of intracranial stenosis lacked robust prospe
- Bringing Chronic Daily Headache Into Focushttps://practicalneurology.com/diseases-diagnoses/headache-pain/PN0305FeaChronicHeadache-pdf/31481/Updates to IHS Headache Classification: Implications for Clinical PracticeThe International Headache Society (IHS) recently updated its classification of chronic daily headache (CDH), presenting significant changes that impact neurologists and headache specialists. Published in *Cephalalgia* in 2004
- Helping MS Patients Achieve Restful and Restorative Sleephttps://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/pn0308-ms-sleep-feature-pdf/31044/Sleep Disorders in Multiple Sclerosis: Comprehensive Review and Management StrategiesPatients with clinically active multiple sclerosis (MS) frequently report significant daytime fatigue, often ranking it among their top three concerns. This fatigue surpasses that experienced by the general populati
- Expert Opinionhttps://practicalneurology.com/columns/practice-management/expert-opinion/31042/Antiepileptic drugs (AEDs) are increasingly associated with various metabolic bone disorders, including osteomalacia, osteoporosis, and an elevated risk of fractures. Early studies highlighted these risks in institutionalized patients, but recent research extends these findings to outpatient populat
- Movement Disorders Focushttps://practicalneurology.com/diseases-diagnoses/movement-disorders/pn0207-movement-pdf/31216/Movement disorders significantly impair patients’ daily activities and quality of life, necessitating objective assessment tools for both clinical practice and research. Practical Neurology’s two-part series delves into the utilization and evaluation of popular rating scales for various movement dis
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31291/Recent advancements in stroke prevention have been scrutinized through pivotal clinical trials, providing critical insights for healthcare professionals. Last month, the ACTIVE, CHARISMA, and MATCH trials collectively assessed the efficacy of combining aspirin with clopidogrel in over 25,000 stroke
- Epilepsy Essentialshttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/pn0905-epilepsyessentials-pdf/31399/Allergic Reactions to Antiepileptic Drugs: Clinical Insights and ManagementAllergic reactions to antiepileptic drugs (AEDs) are a significant concern for healthcare professionals, presenting primarily as cutaneous manifestations. These reactions range from mild rashes to severe, life-threatening con
- Epilepsy Essentialshttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/0105-epilepsy-pdf/31502/Optimal Referral Practices for Refractory Epilepsy CasesDetermining the appropriate timing for referring patients with challenging epilepsy to specialized epilepsy centers remains a topic of debate among neurologists. Referrals may occur early after initial seizure events to confirm diagnoses or uti
Optic Neuritis: Update on Diagnosis, Management, and Long-term Follow-up
https://practicalneurology.com/columns/practice-management/PN1009_02-php/30879/Specialists share insights on diagnostic tools, prospects for neuroprotective therapies, and the risk of MS.